- Home
- CNTA
as 05-17-2024 4:00pm EST
$.
-
$.
-.%
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 1.0B | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 223.7K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $12.45 | Next Earning Date: | 05-13-2024 |
| Revenue: | $6,853,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
MT Newswires
a month ago
Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS
GlobeNewswire
a month ago
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
MT Newswires
a month ago
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering
GlobeNewswire
a month ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
GlobeNewswire
a month ago
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
GuruFocus.com
2 months ago
Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results
GlobeNewswire
2 months ago